Immune Regulation of Skin Wound Healing: Mechanisms and Novel Therapeutic Targets

• Published in: Advances in wound care (New Rochelle, N.Y.) Vol. 7; no. 7; p. 209
• Main Authors: Larouche, Jacqueline, Sheoran, Sumit, Maruyama, Kenta, Martino, Mikaël M
• Format: Journal Article
• Language: English
• Published: United States 01.07.2018
• Subjects: immune system; immunomodulation; therapeutics; scarring; biomaterials; chronic wounds
• ISSN: 2162-1918
• DOI: 10.1089/wound.2017.0761

The immune system plays a central role in orchestrating the tissue healing process. Hence, controlling the immune system to promote tissue repair and regeneration is an attractive approach when designing regenerative strategies. This review discusses the pathophysiology of both acute and chronic wounds and possible strategies to control the immune system to accelerate chronic wound closure and promote skin regeneration (scar-less healing) of acute wounds. Recent studies have revealed the key roles of various immune cells and immune mediators in skin repair. Thus, immune components have been targeted to promote chronic wound repair or skin regeneration and several growth factors, cytokines, and biomaterials have shown promising results in animal models. However, these novel strategies are often struggling to meet efficacy standards in clinical trials, partly due to inadequate drug delivery systems and safety concerns. Excess inflammation is a major culprit in the dysregulation of normal wound healing, and further limiting inflammation effectively reduces scarring. However, current knowledge is insufficient to efficiently control inflammation and specific immune cells. This is further complicated by inadequate drug delivery methods. Improving our understanding of the molecular pathways through which the immune system controls the wound healing process could facilitate the design of novel regenerative therapies. Additionally, better delivery systems may make current and future therapies more effective. To promote the entry of current regenerative strategies into clinical trials, more evidence on their safety, efficacy, and cost-effectiveness is also needed.